Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test

Neuroscience Letters

Volumn 629, Issue , 2016, Pages 143-148

  Souza, L S ^a   Silva, E F ^a   Santos, W B ^a   Asth, L ^a   Lobao Soares B ^a   Soares Rachetti, V P ^a   Medeiros, I U ^a   Gavioli, E C ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Animal model; Lithium; Mania; Mouse; Psychostimulant; Valproate

Indexed keywords

LITHIUM; VALPROIC ACID; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; TRANQUILIZER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXPLORATORY BEHAVIOR; HIGH RISK BEHAVIOR; HOLE BOARD TEST; HYPERACTIVITY; MALE; MANIA; METHYLPHENIDATE INDUCED MANIA LIKE BEHAVIOR; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; BIPOLAR DISORDER; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; LOCOMOTION; NEUROPSYCHOLOGICAL TEST;

ANIMALS; ANTIMANIC AGENTS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; LITHIUM; LOCOMOTION; MALE; METHYLPHENIDATE; MICE; NEUROPSYCHOLOGICAL TESTS; VALPROIC ACID;

EID: 84978286115     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.06.044     Document Type: Article

References (26)

1. [1] American Psychiatric Association, Bipolar and related disorders. DSM-V: Diagnostic and Statistical Manual of Mental Disorders, fifth ed., 2013, American Psychiatric Association, Arlington, 123–154.
2. [2] Miller, S., Dell'Osso, B., Ketter, T.A., The prevalence and burden of bipolar depression. J. Affect. Disord. 169 (2014), S3–S11.
3. [3] Craddock, N., Sklar, P., Genetics of bipolar disorder. Lancet 381 (2013), 1654–1662.
4. [4] Marangoni, C., Hernandez, M., Faedda, G.L., The role of environmental exposures as risk factors for bipolar disorder: a systematic review of longitudinal studies. J. Affect. Disord. 193 (2016), 165–174.
5. [5] Cosgrove, V.E., Kelsoe, J.R., Suppes, T., Toward a valid animal model of bipolar disorder: how the research domain criteria help bridge the clinical-basic science divide. Biol. Psychiatry 79 (2016), 62–70.
6. [6] Kato, T., Kubota, M., Kasahara, T., Animal models of bipolar disorder. Neurosci. Biobehav. Rev. 31 (2007), 832–842.
7. [7] Young, J.W., Dulcis, D., Investigating the mechanism(s) underlying switching between states in bipolar disorder. Eur. J. Pharmacol. 759 (2015), 151–162.
8. [8] Severus, E., Schaaff, N., Möller, H.J., State of the art: treatment of bipolar disorders. CNS Neurosci. Ther. 18 (2012), 214–218.
9. [9] Goodwin, G.M., Haddad, P.M., Ferrier, I.N., Aronson, J.K., Barnes, T., Cipriani, A., Coghill, D.R., Fazel, S., Geddes, J.R., Grunze, H., Holmes, E.A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I.C., McAllister-Williams, H., Miklowitz, D.R., Morriss, R., Munafò, M., Paton, C., Saharkian, B.J., Saunders, K., Sinclair, J., Taylor, D., Vieta, E., Young, A.H., Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Associationfor Psychopharmacology. J. Psychopharmacol. 30:6 (Jun) (2016), 495–553.
10. [10] Machado-Vieira, R., Kapczinski, F., Soares, J.C., Perspectives for the development of animal models of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004), 209–224.
11. [11] Kato, T., Kasahara, T., Kubota-Sakashita, M., Kato, T.M., Nakajima, K., Animal models of recurrent or bipolar depression. Neuroscience 321 (2016), 189–196.
12. [12] Young, J.W., Henry, B.L., Geyer, M.A., Predictive animal models of mania: hits, misses and future directions. Br. J. Pharmacol. 164 (2011), 1263–1284.
13. [13] Sharma, A.N., Fries, G.R., Galvez, J.F., Valvassori, S.S., Soares, J.C., Carvalho, A.F., Quevedo, J., Modeling mania in preclinical settings: a comprehensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry 66 (2016), 22–34.
14. [14] Logan, R.W., McClung, C.A., Animal models of bipolar mania: the past, present and future. Neuroscience 321 (2015), 163–188.
15. [15] Pereira, M., Martynhak, B.J., Baretta, I.P., Correia, D., Siba, I.P., Andreatini, R., Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci. Lett. 500 (2011), 95–98.
16. [16] Barbosa, F.J., Hesse, B., de Almeida, R.B., Baretta, I.P., Boerngen-Lacerda, R., Andreatini, R., Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol. Rep. 63 (2011), 64–70.
17. [17] Arunagiri, P., Rajeshwaran, K., Shanthakumar, J., Tamilselvan, T., Balamurugan, E., Combination of omega-3 fatty acids lithium, and aripiprazole reduces oxidative stress in brain of mice with mania. Biol. Trace Elem. Res. 160 (2014), 409–417.
18. [18] Nogoceke, F.P., Barcaro, I.M., de Sousa, D.P., Andreatini, R., Antimanic-like effects of (R)-(−)-carvone and (S)-(+)-carvone in mice. Neurosci. Lett. 619 (2016), 43–48.
19. [19] van den Buuse, M., Garner, B., Gogos, A., Kusljic, S., Importance of animal models in schizophrenia research. Aust. N. Z. J. Psychiatry 39 (2005), 550–557.
20. [20] Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., Altman, D.G., NC3Rs reporting guidelines working group, animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 160 (2010), 1577–1579.
21. [21] Tonelli, D.A.G., Pereira, M., Siba, I.P., Martynhak, B.J., Correia, D., Casarotto, P.C., Biojone, C., Guimarães, F.S., Joca, S.L., Andreatini, R., The antimanic-like effect of phenytoin and carbamazepine on methylphenidate-induced hyperlocomotion: role of voltage-gated sodium channels. Fundam. Clin. Pharmacol. 27 (2013), 650–655.
22. [22] Young, J.W., Minassian, A., Paulus, M.P., Geyer, M.A., Perry, W., A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci. Biobehav. Rev. 31 (2007), 882–896.
23. [23] Perry, W., Minassian, A., Henry, B., Kincaid, M., Young, J.W., Geyer, M.A., Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res. 178 (2010), 84–91.
24. [24] Perry, W., Minassian, A., Paulus, M.P., Young, J.W., Kincaid, M.J., Ferguson, E.J., Henry, B.L., Zhuang, X., Masten, V.L., Sharp, R.F., Geyer, M.A., A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch. Gen. Psychiatry 66 (2009), 1072–1080.
25. [25] Prut, L., Belzung, C., The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463 (2003), 3–33.
26. [26] Zhou, Z., Wang, Y., Tan, H., Bharti, V., Che, Y., Wang, J.F., Chronic treatment with mood stabilizer lithium inhibits amphetamine-induced risk-taking manic-like behaviors. Neurosci. Lett. 603 (2015), 84–88.